Documenta Ophthalmologica

, Volume 93, Issue 3, pp 193–198 | Cite as

Effect of topical cyclosporin A on Thygeson's superficial punctate keratitis

  • Jose M. Benitez Del Castillo
  • Javier Benitez Del Castillo
  • Julian Garcia-Sanchez


Thygeson's superficial punctate keratitis (Thygeson's SPK) is a distinct clinical entity, characterized by round conglomerates of discrete, granular, white-gray, fine intraepithelial dots without conjuctival involvement. The only effective treatment with regard to relieving symptoms and diminishing lesions has been topical corticosteroids, but their prolonged use can be associated with severe side-effects. The purpose of this study is to present the long-term results of the use of 2% topical cyclosporin A in olive oil in Thygeson's SPK. Eight patients diagnosed as having Thygeson's SPK were included. All the patients were treated with 2% cyclosporin dissolved in olive oil four times a day for three months, and two times a day for one month before withdrawing therapy. The follow-up period ranged from twelve to twenty-five months. The number of corneal lesions varied between 5 and 15 before treatment. After cyclosporin treatment, no corneal lesion was observed and the cornea remained clear after the follow-up period. In conclusion, 2% cyclosporin in olive oil is a safe alternative to corticosteroids in the treatment of Thygeson's SPK, and resulted in satisfactory control of the condition.

Key words

Thygeson's superficial punctate keratitis cyclosporin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Thygeson P. Superficial punctate keratitis (SPK). JAMA 1950; 144: 1544–1549.Google Scholar
  2. 2.
    Braley AB, Alexander RC. Superficial punctate keratitis: isolation of a virus. Arch Ophthalmol 1953; 50: 147–254.Google Scholar
  3. 3.
    Lemp MA, Chambera RW Jr, Lundy J. Virus isolate in superficial punctate keratitis. Arch Ophthalmol 1974; 91: 8–10.PubMedGoogle Scholar
  4. 4.
    Forstot SL, Binder PS. treatment of Thygesonss superficial punctate keratopathy with soft contact lenses. Am J Ophthalmol 1979; 88: 186–189.PubMedGoogle Scholar
  5. 5.
    Schwab IR, Thygeson P. Thygeson superficial punctate keratopathy. In Pepose JS, Holland GN, Wilhelmus KR, editors. Ocular infection and immunity. St Louis: Mosby, 1996: 403–407.Google Scholar
  6. 6.
    Darrell RW. Thygeson's superficial punctate keratitis: natural history and association with HLA DR3. Trans Am Ophthalmol Soc 1982; 79: 486–516.Google Scholar
  7. 7.
    Tabbara KF, Ostler HB, Dawson C, Oh J. Thygeson's superficial punctate keratitis. Ophthalmology 1981; 88: 75–77.PubMedGoogle Scholar
  8. 8.
    Nesburn AB, Lowe III GH, Lepoff NJ, Maguen H. Effect of topical trifluridine on Thygeson's superficial punctate keratitis. Ophthalmology 1984; 91: 1188–1192.PubMedGoogle Scholar
  9. 9.
    Holsclaw DS, Wong IG, Sherman M. Masked trial of topical cyclosporine A in the treatment of refractory Thygeson's superficial punctate keratitis. Invest Ophthalmol Vis Sci 1994; 35 (ARVO abstract): 1302.Google Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • Jose M. Benitez Del Castillo
    • 1
  • Javier Benitez Del Castillo
    • 1
  • Julian Garcia-Sanchez
    • 1
  1. 1.Facultad de MedicinaInstituto de Investigaciones Oftamologicas Ramon CastroviejoMadridSpain

Personalised recommendations